- FDA Widens Path for Rare-Disease Treatments With New Approval The Wall Street Journal
- RETA Stock Skyrockets As FDA Approves Reata Phama’s Neurological Drug | Investor’s Business Daily Investor’s Business Daily
- Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia businesswire.com
- FDA approves Reata’s treatment for rare neurological disease STAT
- Reata Pharmaceuticals up 192% on Friedreich’s ataxia drug omaveloxolone approval (RETA) Seeking Alpha
- View Full Coverage on Google News
Read More: FDA Widens Path for Rare-Disease Treatments With New Approval – The Wall Street